The efficacy and safety of secukinumab, a fully human anti‐interleukin‐17A monoclonal
antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which …

Background Psoriasis is associated with metabolic, liver and cardiovascular comorbidity.
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin …

Background Efficacy data on therapies for patients with psoriasis who have failed tumour
necrosis factor (TNF)‐α inhibitor therapy is limited. Objectives To determine the effectiveness …

Background The efficacy and safety of secukinumab, an interleukin-17 inhibitor, as systemic
treatment for patients with moderate-to-severe psoriasis have been demonstrated, but real …

DEAR EDITOR, Recent studies have shown that biological drugs approved for treating
psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the …

Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …

Background The social stigma and chronicity of psoriasis significantly affect health‐related
quality of life (HRQoL). Objective We examined the effect of three regimens of secukinumab …

Background Randomized controlled trials of secukinumab have shown sustained efficacy
and a favourable safety profile in multiple manifestations of psoriatic disease. Objectives To …

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key
clinical symptoms, including itching, pain, and scaling. PsO is associated with a high …

Summary Background Interleukin (IL)‐17A has major proinflammatory activity in psoriatic
lesional skin. Objectives To assess the efficacy and safety of secukinumab, a fully human …